NeoGenomics (NEO) Upgraded at BidaskClub

BidaskClub upgraded shares of NeoGenomics (NASDAQ:NEO) from a sell rating to a hold rating in a report released on Monday.

Several other brokerages have also recently issued reports on NEO. Scotiabank set a $22.00 price objective on NeoGenomics and gave the stock an outperform rating in a report on Wednesday, January 3rd. Janney Montgomery Scott reaffirmed a buy rating on shares of NeoGenomics in a report on Thursday, October 26th. Zacks Investment Research raised NeoGenomics from a sell rating to a hold rating in a research report on Friday, October 20th. CIBC set a $19.00 price target on NeoGenomics and gave the stock a neutral rating in a research report on Wednesday, January 3rd. Finally, Royal Bank of Canada set a $23.00 price target on NeoGenomics and gave the stock an outperform rating in a research report on Wednesday, January 3rd. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $15.83.

NeoGenomics (NASDAQ:NEO) opened at $7.23 on Monday. The stock has a market capitalization of $602.27, a price-to-earnings ratio of 149.80, a P/E/G ratio of 3.02 and a beta of 0.57. NeoGenomics has a 1-year low of $7.08 and a 1-year high of $11.63. The company has a current ratio of 2.14, a quick ratio of 1.99 and a debt-to-equity ratio of 0.57.

Institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new position in NeoGenomics during the third quarter worth $369,000. Bank of New York Mellon Corp increased its position in NeoGenomics by 4.1% during the third quarter. Bank of New York Mellon Corp now owns 982,560 shares of the medical research company’s stock worth $10,935,000 after buying an additional 38,776 shares in the last quarter. Goldman Sachs Group Inc. increased its position in NeoGenomics by 79.2% during the second quarter. Goldman Sachs Group Inc. now owns 30,678 shares of the medical research company’s stock worth $275,000 after buying an additional 13,561 shares in the last quarter. Janus Henderson Group PLC increased its position in NeoGenomics by 50.3% during the third quarter. Janus Henderson Group PLC now owns 3,464,655 shares of the medical research company’s stock worth $38,562,000 after buying an additional 1,159,888 shares in the last quarter. Finally, Uniplan Investment Counsel Inc. increased its position in NeoGenomics by 7.1% during the third quarter. Uniplan Investment Counsel Inc. now owns 839,310 shares of the medical research company’s stock worth $9,341,000 after buying an additional 55,506 shares in the last quarter. 83.27% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “NeoGenomics (NEO) Upgraded at BidaskClub” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://sportsperspectives.com/2018/02/09/neogenomics-neo-upgraded-at-bidaskclub.html.

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply